Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신수민 | * |
dc.date.accessioned | 2023-07-31T16:31:14Z | - |
dc.date.available | 2023-07-31T16:31:14Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 0003-4932 | * |
dc.identifier.other | OAK-33523 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/265335 | - |
dc.description.abstract | Objective: The aim of this study was to validate the International Association for the Study of Lung Cancer (IASLC) residual tumor classification in patients with stage III-N2 non-small cell lung cancer (NSCLC) undergoing neoadjuvant concurrent chemoradiotherapy (nCCRT) followed by surgery. Background: As adequate nodal assessment is crucial for determining prognosis in patients with clinical N2 NSCLC undergoing nCCRT followed by surgery, the new classification may have better prognostic implications. Methods: Using a registry for thoracic cancer surgery at a tertiary hospital in Seoul, Korea, between 2003 and 2019, we analyzed 910 patients with stage III-N2 NSCLC who underwent nCCRT followed by surgery. We classified resections using IASLC criteria: complete (R0), uncertain (R[un]), and incomplete resection (R1/R2). Recurrence and mortality were compared using adjusted subdistribution hazard model and Cox-proportional hazards model, respectively. Results: Of the 96.3% (n = 876) patients who were R0 by Union for International Cancer Control (UICC) criteria, 34.5% (n = 3O2) remained R0 by IASLC criteria and 37.6% (n = 329) and 28% (n = 245) migrated to R(un) and R1, respectively. Most of the migration from UICC-R0 to lASLC-R(un) and IASLC-R1/R2 occurred due to inadequate nodal assessment (85.5%) and extracapsular nodal extension (77.6%), respectively. Compared to R0, the adjusted hazard ratios in R(un) and R1/R2 were 1.20 (95% confidence interval, 0.94-1.52), 1.50 (1.17-1.52) (P fortrend =.001) for recurrence and 1.18 (0.93-1.51) and 1.51 (1.17-1.96) for death (P for trend =.002). Conclusions: The IASLC R classification has prognostic relevance in patients with stage III-N2 NSCLC undergoing nCCRT followed by surgery. The IASLC classification will improve the thoroughness of intraoperative nodal assessment and the completeness of resection. © 2023 Lippincott Williams and Wilkins. All rights reserved. | * |
dc.language | English | * |
dc.publisher | Wolters Kluwer Health | * |
dc.subject | lung cancer | * |
dc.subject | N2 | * |
dc.subject | neoadjuvant concurrent chemoradiotherapy | * |
dc.subject | residual tumor | * |
dc.subject | surgery | * |
dc.title | Validation of the IASLC Residual Tumor Classification in Patients with Stage III-N2 Non-Small Cell Lung Cancer Undergoing Neoadjuvant Chemoradiotherapy Followed by Surgery | * |
dc.type | Article | * |
dc.relation.issue | 6 | * |
dc.relation.volume | 277 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | E1355 | * |
dc.relation.lastpage | E1363 | * |
dc.relation.journaltitle | Annals of Surgery | * |
dc.identifier.doi | 10.1097/SLA.0000000000005414 | * |
dc.identifier.wosid | WOS:000992555200045 | * |
dc.identifier.scopusid | 2-s2.0-85135158476 | * |
dc.author.google | Lee J. | * |
dc.author.google | Hong Y.S. | * |
dc.author.google | Lee G. | * |
dc.author.google | Kang D. | * |
dc.author.google | Yun J. | * |
dc.author.google | Jeon Y.J. | * |
dc.author.google | Shin S. | * |
dc.author.google | Cho J.H. | * |
dc.author.google | Choi Y.S. | * |
dc.author.google | Kim J. | * |
dc.author.google | Zo J.I. | * |
dc.author.google | Shim Y.M. | * |
dc.author.google | Guallar E. | * |
dc.author.google | Cho J. | * |
dc.author.google | Kim H.K. | * |
dc.contributor.scopusid | 신수민(55154397000) | * |
dc.date.modifydate | 20240315141520 | * |